Dipal Doshi, President and CEO at Entrada Therapeutics, Inc. (TRDA), sold 28,180 shares at $15.01 ($423K) on 2022-12-28, disclosed to the SEC on 2022-12-29.
Open-market sale of $423k TRDA by President and CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.80 | 600 | $9K | 2.1% |
| 2 | $15.04 | 9,069 | $136K | 32.2% |
| 3 | $15.04 | 9,069 | $136K | 32.2% |
| 4 | $15.01 | 4,521 | $68K | 16.0% |
| 5 | $15.01 | 4,521 | $68K | 16.0% |
| 6 | $15.01 | 400 |
| $6K |
| 1.4% |
| Total | $15.02 avg | 28,180 | $423K | 100% |
| Filing → |
| TRDA | SELL | 2024-05-20 | $45K | — | Filing → |
| TRDA | SELL | 2024-02-20 | $15K | — | Filing → |
| TRDA | SELL | 2024-01-18 | $16K | — | Filing → |